The WATCHMAN(TM) Left Atrial Appendage Closure Device from Boston Scientific is an implant used to block the left atrial appendage of the heart, a common area for blood clot formations in patients ...

They randomly assigned 803 patients to left atrial appendage closure with the Watchman FLX device and 797 patients to oral anticoagulation therapy from November 2019 through June 2021. Mean ...

Boston Scientific’s Watchman left atrial appendage (LAA) closure device to prevent stroke resulted in significantly less bleeding after an ablation procedure than taking blood thinners ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC ...

The Watchman FLX device demonstrated superior safety and reduced bleeding risk compared to oral anticoagulation. Findings may prompt guideline changes, suggesting left atrial appendage closure as ...

According to a Precedence Research report, the global left atrial appendage closure devices market is projected to grow around $7.01 billion by 2034, at a compound annual growth rate of 14.1% from ...

Boston Scientific has reported positive three-year data from the OPTION global trial of the WATCHMAN FLX left atrial appendage closure (LAAC) device in individuals with atrial fibrillation ...

establishing uniform coverage for percutaneous left atrial appendage closure (LAAC) devices such as the Watchman procedure. However, individuals must meet specific criteria. Learn more about the ...

Medicare has requirements an individual must meet to qualify for left atrial appendage closure devices, and the Watchman implant device is a type of atrial appendage closure device. Medicare parts ...